Enimmune Biotech Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 36

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 3

Enimmune Biotech General Information

Description

Enimmune Corp is primarily engaged in the research and development and trading of vaccines, testing reagents and biotechnology services, etc., as well as trading of related western medicines.

Contact Information

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • 18 F.-2, No. 76, Sec. 2, Dunhua S. Rd.
  • Daan District
  • Taipei
  • Taiwan
+886 02
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 18 F.-2, No. 76, Sec. 2, Dunhua S. Rd.
  • Daan District
  • Taipei
  • Taiwan
+886 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enimmune Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. IPO 09-Jul-2024 Announced Generating Revenue
2. Later Stage VC 01-Jan-2020 Completed Generating Revenue
1. Early Stage VC 01-Jun-2015 Completed Generating Revenue
To view Enimmune Biotech’s complete valuation and funding history, request access »

Enimmune Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enimmune Biotech Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Diamond Biofund Venture Capital Minority
Maxceed Capital Family Office Minority
Chung Ying Investment Development Company Asset Manager Minority
To view Enimmune Biotech’s complete investors history, request access »

Enimmune Biotech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Enimmune Biotech’s complete esg history, request access »

Enimmune Biotech FAQs

  • When was Enimmune Biotech founded?

    Enimmune Biotech was founded in 2014.

  • Where is Enimmune Biotech headquartered?

    Enimmune Biotech is headquartered in Taipei, Taiwan.

  • What is the size of Enimmune Biotech?

    Enimmune Biotech has 36 total employees.

  • What industry is Enimmune Biotech in?

    Enimmune Biotech’s primary industry is Drug Discovery.

  • Is Enimmune Biotech a private or public company?

    Enimmune Biotech is a Private company.

  • What is Enimmune Biotech’s current revenue?

    The current revenue for Enimmune Biotech is .

  • Who are Enimmune Biotech’s investors?

    Diamond Biofund, Maxceed Capital, and Chung Ying Investment Development Company have invested in Enimmune Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process